Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Minerva Cardiology and Angiology 2021 April;69(2) > Minerva Cardiology and Angiology 2021 April;69(2):154-60

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Minerva Cardiology and Angiology 2021 April;69(2):154-60

DOI: 10.23736/S2724-5683.20.05085-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Effects of treprostinil on pulmonary arterial hypertension during surgery for congenital heart disease complicated with severe pulmonary arterial hypertension

Huiwen JIANG 1, Xiaodan YU 2, Lina ZHANG 3, Minxin WANG 1

1 Department of Ultrasonography, Weihai Central Hospital, Weihai, China; 2 Blood Purification Center, Weihai Central Hospital, Weihai, China; 3 Penglai People’s Hospital, Yantai, China



BACKGROUND: The aim of this study is to evaluate the effects of treprostinil injection on the control of pulmonary blood pressure in children with congenital heart disease (CHD) complicated by severe pulmonary arterial hypertension (PAH).
METHODS: Eighty children with CHD complicated by severe pulmonary arterial hypertension admitted to our hospital from January 2015 to June 2018 were selected and randomly divided into a control group (N.=40) and a treatment group (N.=40). Based on standard treatment, the treatment group was intravenously infused with 8-12 ng/kg·min treprostinil, while the control group received the same dose of normal saline. Hemodynamic parameters such as BP, AP, P and SpO2% were monitored before anesthesia induction (T0), before cardiopulmonary bypass (T1), 1 h after cardiopulmonary bypass (T2) and at the end of cardiopulmonary bypass (T3). Pulmonary arterial pressure parameters (PASP, PADP and PAMP) were measured at T1, T2 and T3 by transesophageal echocardiography.
RESULTS: For the treatment group, the HR values at T2 and T3 were lower than that at T0 (P<0.05). For the control group, HR at T3 was lower than that at T0 (P<0.05). HR at T3 of the treatment group was lower than that of the control group (P<0.05). SpO2 of the treatment group was higher than that of the control group at T3 (P<0.05). At T2 and T3, PASP, PADP and PAMP of both groups were lower than those before surgery (P<0.05), and the values of the treatment group were lower than those of the control group (P<0.05).
CONCLUSIONS: Treprostinil can improve cardiac function and reduce pulmonary circulation resistance in PAH children.


KEY WORDS: Heart diseases; Pulmonary arterial hypertension; Treprostinil; Echocardiography

inizio pagina